[1] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166.
[2] Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2023, 8(1): 20-30.
[3] Tilg H, Byrne CD, Targher G. NASH drug treatment development: challenges and lessons[J]. Lancet Gastroenterol Hepatol, 2023, 8(10): 943-954.
[4] ClinicalTrials.gov. A phase 3 study to evaluate the efficacy and safety of MGL-3196(resmetirom)in patients with NASH and fibrosis (MAESTRO-NASH). https://clinicaltrials.gov/ct2/show/NCT03900429.
[5] Sanyal A J, Ratziu V, Loomba R et al. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis[J]. J Hepatol, 2023, 79(5): 1110-1120.
[6] Chang X, Lv C, Wang B, et al. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis. Published online August 23, 2023. 10.1097/HEP.0000000000000563
[7] Sun Y, Chen W, Chen S, et al. Regression of liver fibrosis in patients on hepatitis B therapy is associated with decreased liver-related events[J]. Clin Gastroenterol Hepatol. 2023 Nov 30; S1542-3565(23)00955-2.
[8] Simon TG, Roelstraete B, Hagstrom H et al. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study[J]. J Hepatol, 2023, 79(6): 1366-1373.
[9] Rinella ME, Dufour JF, Anstee QM et al. Non-invasive evaluation of response to obeticholic acid in patients with nash: results from the regenerate study[J]. J Hepatol, 2022,76(3):536-548.
[10] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.
[11] Wattacheril JJ, Abdelmalek MF, Lim JK, et al. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review[J]. Gastroenterology, 2023, 165(4): 1080-1088.
[12] Wang B, Zhou J, Wu X et al. Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under VirologicalS uppression: A Randomized Open-Label Trial. Am J Gastroenterol. Published online December 7, 2023. 10.14309/ajg.0000000000002569
[13] Tonon M, Balcar L, Semmler G et al. Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating event[J]. Hepatology, 2023, 78(4): 1149-1158.
[14] Wang Q, Zhao H, Deng Y et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77(6): 1564-1572.
[15] Hui V, Wong G, Wong V et al. Baveno vii criteria for recompensation predict transplant-free survival in patients with hepatitis b-related decompensated cirrhosis[J]. J Hep Rep, 2023,5(9):100814. |
